These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21802442)

  • 21. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.
    Okamoto LE; Shibao C; Gamboa A; Choi L; Diedrich A; Raj SR; Black BK; Robertson D; Biaggioni I
    Hypertension; 2012 Mar; 59(3):650-6. PubMed ID: 22311903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice.
    Tsuchida R; Kubo M; Kuroda M; Shibasaki Y; Shintani N; Abe M; Köves K; Hashimoto H; Baba A
    J Pharmacol Sci; 2009 Mar; 109(3):396-402. PubMed ID: 19270432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function.
    Shibao C; Raj SR; Gamboa A; Diedrich A; Choi L; Black BK; Robertson D; Biaggioni I
    Hypertension; 2007 Jul; 50(1):47-53. PubMed ID: 17515448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atomoxetine attenuates dextroamphetamine effects in humans.
    Sofuoglu M; Poling J; Hill K; Kosten T
    Am J Drug Alcohol Abuse; 2009; 35(6):412-6. PubMed ID: 20014909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methamphetamine self-administration in humans during D-amphetamine maintenance.
    Pike E; Stoops WW; Hays LR; Glaser PE; Rush CR
    J Clin Psychopharmacol; 2014 Dec; 34(6):675-81. PubMed ID: 25154010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical pharmacology of intranasal l-methamphetamine.
    Mendelson JE; McGlothlin D; Harris DS; Foster E; Everhart T; Jacob P; Jones RT
    BMC Clin Pharmacol; 2008 Jul; 8():4. PubMed ID: 18644153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individual differences in responses to ethanol and d-amphetamine: a within-subject study.
    Holdstock L; de Wit H
    Alcohol Clin Exp Res; 2001 Apr; 25(4):540-8. PubMed ID: 11329494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period.
    Lile JA; Stoops WW; Hays LR; Rush CR
    Am J Drug Alcohol Abuse; 2008; 34(6):721-9. PubMed ID: 18855244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.
    Kirkpatrick MG; Gunderson EW; Perez AY; Haney M; Foltin RW; Hart CL
    Psychopharmacology (Berl); 2012 Jan; 219(1):109-22. PubMed ID: 21713605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.
    Lile JA; Babalonis S; Emurian C; Martin CA; Wermeling DP; Kelly TH
    J Clin Pharmacol; 2011 Jun; 51(6):888-98. PubMed ID: 20671295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans.
    Kirkpatrick MG; Gunderson EW; Johanson CE; Levin FR; Foltin RW; Hart CL
    Addiction; 2012 Apr; 107(4):783-91. PubMed ID: 22050030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.
    Pike E; Stoops WW; Rush CR
    Pharmacol Biochem Behav; 2016; 150-151():87-93. PubMed ID: 27697553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intranasal methamphetamine on metacognition of agency.
    Kirkpatrick MG; Metcalfe J; Greene MJ; Hart CL
    Psychopharmacology (Berl); 2008 Mar; 197(1):137-44. PubMed ID: 18043908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy.
    Rabiey A; Hassani-Abharian P; Farhad M; Moravveji AR; Akasheh G; Banafshe HR
    Arch Iran Med; 2019 Dec; 22(12):692-698. PubMed ID: 31823620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.
    De La Garza R; Zorick T; London ED; Newton TF
    Drug Alcohol Depend; 2010 Jan; 106(2-3):173-80. PubMed ID: 19781865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Norepinephrine and stimulant addiction.
    Sofuoglu M; Sewell RA
    Addict Biol; 2009 Apr; 14(2):119-29. PubMed ID: 18811678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
    Gaillez C; Sorbara F; Perrin E
    Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal Oxytocin Does Not Modulate Responses to Alcohol in Social Drinkers.
    Vena A; King A; Lee R; de Wit H
    Alcohol Clin Exp Res; 2018 Sep; 42(9):1725-1734. PubMed ID: 29917245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants.
    Carpenter LL; Milosavljevic N; Schecter JM; Tyrka AR; Price LH
    J Clin Psychiatry; 2005 Oct; 66(10):1234-8. PubMed ID: 16259536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.